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Introduction: The risk of acute kidney injury (AKI) with the use of albumin-containing fluids compared to starches
in the surgical intensive care setting remains uncertain. We evaluated the adjusted risk of AKI associated with
colloids following cardiac surgery.
Methods: We performed a retrospective cohort study of patients undergoing on-pump cardiac surgery in a tertiary
care center from 2008 to 2010. We assessed crystalloid and colloid administration until 36 hours after surgery.
AKI was defined by the RIFLE (risk, injury, failure, loss and end-stage kidney disease) risk and Acute Kidney Injury
Network (AKIN) stage 1 serum creatinine criterion within 96 hours after surgery.
Results: Our cohort included 984 patients with a baseline glomerular filtration rate of 72 ± 19 ml/min/1.73 m2.
Twenty-three percent had a reduced left ventricular ejection fraction (LVEF), thirty-one percent were diabetics and
twenty-three percent underwent heart valve surgery. The incidence of AKI was 5.3% based on RIFLE risk and 12.0%
based on the AKIN criterion. AKI was associated with a reduced LVEF, diuretic use, anemia, heart valve surgery,
duration of extracorporeal circulation, hemodynamic instability and the use of albumin, pentastarch 10% and
transfusions. There was an important dose-dependent AKI risk associated with the administration of albumin,
which also paralleled a higher prevalence of concomitant risk factors for AKI. To address any indication bias, we
derived a propensity score predicting the likelihood to receive albumin and matched 141 cases to 141 controls
with a similar risk profile. In this analysis, albumin was associated with an increased AKI risk (RIFLE risk: 12% versus 5%,
P = 0.03; AKIN stage 1: 28% versus 13%, P = 0.002). We repeated this methodology in patients without postoperative
hemodynamic instability and still identified an association between the use of albumin and AKI.
Conclusions: Albumin administration was associated with a dose-dependent risk of AKI and remained significant
using a propensity score methodology. Future studies should address the safety of albumin-containing fluids on kidney
function in patients undergoing cardiac surgery.Introduction
Acute kidney injury (AKI) following cardiac surgery is
prevalent and associated with considerable morbidity
and mortality [1,2]. Perioperative resuscitation solutions
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unless otherwise stated.colloids in the hope of facilitating intravascular volume
repletion [3,4]. However, synthetic starches are now
recognized as an independent risk factor for AKI in
critically ill patients [5,6]. The Kidney Disease Improving
Global Outcome (KDIGO) Clinical Practice Guidelines
for AKI favor isotonic crystalloids over colloids in patients
at risk for or presenting with AKI in the absence of
hemorrhagic shock [7]. Whether this applies equally to
different synthetic starches and albumin is uncertain.
Study results regarding administration of albumin-
containing fluids have been conflicting. Hyperoncotic
albumin has demonstrated a clear benefit in patients withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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albumin has been associated with a fivefold increased
risk of AKI [10]. A recent European consensus statement
recommends withholding hyperoncotic albumin use in
critically ill patients outside of clinical trials [10,11].
The recently published Albumin Italian Outcome Sepsis
(ALBIOS) Study, a randomized controlled trial (RCT)
on the effect of hyperoncotic albumin (20%) versus
crystalloids in hypoalbuminemic patients with severe
sepsis and septic shock, did not show any difference
in mortality and AKI between the groups [12]. However,
the timing of AKI in relation to albumin administration
>was not detailed. The use of iso-oncotic albumin in a
heterogeneous population of critically ill patients has also
been studied in a large, multicenter RCT: the Saline versus
Albumin Fluid Evaluation (SAFE) study. In that RCT, the
investigators concluded that iso-oncotic albumin adminis-
tration is safe from a survival perspective [4,13] and found
no differences in organ dysfunction or duration of renal re-
placement therapy (RRT). However, kidney function was
not independently reported, and only severe cases of AKI
were collected. No data specifically on the safety of albumin
as it relates to kidney function after cardiac surgery exist.
In 2009, we reported a dose-dependent risk of AKI
using pentastarch 10% (250 kDa/0.45) following cardiac
surgery [6]. Since then, our practice has shifted toward
the use of hydroxyethyl starch (HES) 6% (130 kDa/0.4)
and albumin for volume expansion in unstable patients, and
more recently it has shifted toward the use of crystalloids
with or without albumin. In the present study, we
hypothesized that both synthetic starches and albumin-
containing solutions are independently associated with AKI
in a dose-dependent fashion following cardiac surgery.
Materials and methods
Study design and setting
We conducted a retrospective cohort study of patients
who underwent on-pump cardiac surgery between 1
January 2008 and 31 December 2010 at the Hôpital
du Sacré-Coeur de Montréal, a tertiary care teaching
hospital. The intensive care unit is a 24-bed mixed
medical-surgical and trauma unit. The research ethics
board of the Hôpital du Sacré-Coeur de Montréal approved
the study protocol and waived the need for consent from
the study participants.
Patients
We included all adult patients who required either
coronary artery bypass graft (CABG) and/or valve replace-
ment and who were hospitalized at least 96 hours after
surgery. Patients known to have end-stage renal disease
(ESRD) or AKI (defined on the basis of the RIFLE
(risk, injury, failure, loss and end-stage kidney disease)
serum creatinine criterion), kidney transplant, autoimmunekidney disease or kidney cancer were excluded as being
those who had undergone urgent aortic surgeries. ESRD
was defined as a baseline creatinine clearance inferior to 15
ml/min/1.73 m2 or treatment with dialysis [14]. Data were
obtained from patients’ charts on a prevalidated case report
form by three investigators (PB, AC and LTN).
Data collection
We recorded baseline risk factors for AKI, including patient
demographics, history of hypertension, diabetes, peripheral
vascular disease, stroke, recent myocardial infarction (within
7 days before surgery), left ventricular ejection fraction
(LVEF) and preoperative hemoglobin level. We assessed any
use of angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers, nonsteroidal anti-inflammatory
drugs, contrast agents and diuretics within 5 days before
surgery. Preoperative kidney function was estimated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) creatinine equation [15].
We collected type of surgery (elective or urgent; CABG
only or heart valve surgery), as well as perioperative vari-
ables, including the Sequential Organ Failure Assessment
(SOFA) score for cardiovascular system immediately after
surgery [16], use of an intra-arterial balloon pump (IABP),
duration of extracorporeal circulation (ECC), and the need
for reintervention. We recorded the amount of crystalloids,
colloids and blood product transfusions, including red
blood cells (RBCs), platelets and fresh frozen plasma (FFP)
administered from surgery until 36 hours postoperatively.
Colloids consisted of pentastarch 10% (250 kDa/0.45
Pentaspan; Bristol-Myers Squibb, Montreal, QC, Canada),
6% HES (130 kDa/0.4 Voluven™; Fresenius Kabi, Richmond
Hill, ON, Canada) and human albumin 5% and 25%
(Alburex™ 5 and 25; CSL Behring, Ottawa, ON, Canada).
Synthetic colloids are expressed as the patient’s weight in
milliliters per kilogram. The amount of albumin 5% and 25%
given was converted in absolute grams of albumin, added,
and expressed by the patient’s weight in grams per kilogram.
Definitions
Glomerular filtration rate (GFR) was estimated by using the
CKD-EPI formula [15]. Postoperative AKI was assessed
using the RIFLE serum creatinine criterion as described in
our previous publication [6]. We also assessed the Acute
Kidney Injury Network (AKIN) stage 1 serum creatinine
criterion [17]. The highest postoperative serum creatinine
within 96 hours after surgery was compared with the
preoperative creatinine value. Missing values were found
in less than 1% of individuals for each variable.
Statistical analysis
Normally distributed variables were expressed as mean ±
standard deviation and compared using Student’s t-test.
Nonparametric continuous variables were expressed as
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the Mann–Whitney U test, and categorical variables
were expressed in percentages and compared using
the Pearson’s χ2 test. Spearman’s correlation was used to
perform a trend test between tertiles of colloids and AKI.
Because colloids are indicated for restoration of the
circulating volume, they are given in situations associated
with AKI in which it may be difficult to distinguish
the effect of the colloid from the underlying condition.
Adjustment for an indication bias was further assessed
using a propensity score. This methodology permits the
comparison of patients who received a colloid to con-
trols with a similar AKI risk profile. We followed the
Strengthening the Reporting of Observational Studies
in Epidemiology guidelines [18]. The propensity score
was obtained using every variable statistically associated
with the prescription of the colloid of interest. These were
used in a logistic regression in which each variable was
forced into the final model with the suggested ratio of
approximately 1:10 variable/event. We then derived, for
each patient, the probability (propensity score) of receiving
colloids and compared exposed to unexposed patients in a
1:1 ratio, matched by the closest propensity score up to a
±0.05 difference [19]. This suggested that caliper size was
very similar to another proposed caliper size defined by a
0.2 standard deviation of the propensity score (see Results).Table 1 Preoperative, perioperative and postoperative patien
Preoperative characteristics Per
Age (yr) 66 ± 10 Use
Female (%) 25 Hea
Caucasian (%) 94 CAB
Active smoking status (%) 27 Dur
Initial GFR (ml/min/1.73 m2) 72 ± 19 Urg
Comorbidities Rein
Hypertension (%) 72 Pos
Diabetes (%) 31 Peri
Hyperlipidemia (%) 69 R
Peripheral vascular disease (%) 8 P
Stroke (%) 7 F
MI within the past 7 days (%) 13
LVEF ≤35%, 36% to 49%, ≥50% (%) 9, 14, 77 AKI
Drugs used within 5 days prior to surgery A
Diuretics (%) 34 R
RASB (%) 59 R
NSAIDs (%) 9 R
Contrast agent for angiography (%) 26
Preoperative hemoglobin (g/L) 130 ± 17
aResults are expressed as mean ± standard deviation, median (interquartile range (IQ
Injury Network; CABG, Coronary artery bypass graft; ECC, Extracorporeal circulation;
Myocardial infarction; NSAIDs, Nonsteroidal anti-inflammatory drugs; RASB, Renin an
disease; SOFA, Sequential Organ Failure Assessment.Each control patient was matched to only one treated
patient (that is, there was no replacement) [20]. We
then assessed whether treated and untreated groups
balanced in terms of predictors of AKI. We also repeated
this methodology in the subset of patients without
hemodynamic instability as defined by a postoperative
cardiovascular SOFA score of zero.
In the statistical analyses, we excluded cases with missing
covariates. All P-values were two-tailed, and values <0.05
were considered statistically significant. Analyses were




The characteristics of the 984 individuals included in the
study are detailed in Table 1. The cohort characteristics
included a majority of Caucasian men, mean age of
66 ± 10 years, normal preoperative renal function and a
high prevalence of cardiovascular risk factors. Seventy-seven
percent of individuals had a normal LVEF (≥50%), and 6.3%
required the use of an IABP perioperatively.
Fourteen percent of surgeries were defined as urgent,
and twenty-three percent included valve replacement or
repair. The median duration of ECC was 1.1 hour (IQR,
0.9 to 1.5). The median volume of crystalloids receivedt characteristics (N = 984)a
ioperative and postoperative characteristics
of intra-aortic balloon (%) 6.3
rt valve surgery (%) 23
G (%) 93
ation of ECC (hr) (IQR) 1.1 (0.9 to 1.5)
ent surgery (%) 14
tervention (%) 4
toperative cardiovascular SOFA score ≤2, >2 (%) 51, 49
operative transfusions
ed blood cells (0, 1, 2, ≥3 U) (%) 45, 15, 14, 22
latelets (0, ≤10, >10 U) (%) 80, 17, 3
resh frozen plasma (0, ≤5, >5 U) (%) 80, 16, 4
(%)




R)) or percentage as appropriate. AKI, acute kidney injury; AKIN, Acute Kidney
GFR, Glomerular filtration rate; LVEF, Left ventricular ejection fraction; MI,
giotensin blockade; RIFLE, Risk, injury, failure, loss and end-stage kidney
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eratively was 63 ml/kg (IQR, 49 to 83). Eighty-two
percent, forty-three percent and sixteen percent of
individuals received HES 6%, pentastarch 10% or albumin,
respectively, with median volumes of 13 ml/kg (IQR,
8 to 19) and 9 ml/kg (IQR, 6 to 15) and a median dose of
1.4 g/kg (IQR, 1.1 to 2.2), respectively (Figure 1). RBCs
were given to half of the patients, and FFP and platelets
were both given to 20% of patients. Half of the patients
had a cardiovascular SOFA score >2 after surgery.
Within 96 hours following surgery, RIFLE risk for AKI
occurred in 5.3% of patients, RIFLE injury occurred in
1.9% and RIFLE failure occurred in 0.7%, whereas theFigure 1 Fluid administration from surgery until 36 hours postoperatincidence of AKIN stage 1 was 12.0%. No patient received
RRT within 96 hours following surgery. By 36 hours after
surgery, 52% of AKI defined by RIFLE risk and 64% of
those defined by AKIN stage 1 had occurred (Figure 2).
Predictors of acute kidney injury following cardiac
surgery
Risk factors for AKI using the RIFLE serum creatinine
criterion are shown in Table 2. A preoperative reduced
LVEF, lower hemoglobin and use of diuretics were
predictive of AKI. Perioperatively, valvular surgeries, need
for IABP, duration of ECC, cardiovascular SOFA score and
number of RBCs, FFP transfusions and platelet transfusionsively (N = 984).
Figure 2 Cumulative risk of acute kidney injury during the
96-hour postoperative observation period. AKI, Acute kidney
injury; AKIN, Acute Kidney Injury Network; RIFLE, Risk Injury Failure
Loss and End-stage kidney disease.
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greatest risk for AKI was associated with the use of albumin
(odds ratio (OR), 3.9; 95% confidence interval (CI), 2.1 to
6.8; P < 0.001), marginal with the use of pentastarch 10%
(OR, 1.7; 95% CI, 1.0 to 3.0; P = 0.06) and absent with theTable 2 Variables associated with acute kidney injury as






Preoperative LVEF, ≤35%, 36% to
49%, ≥50% (%)
9, 13, 78 15, 21, 64 0.02
Preoperative use of diuretics (%) 33 56 0.001
Preoperative hemoglobin (g/L) 130 ± 17 123 ± 22 0.002
Heart valve surgery (%) 22 37 0.01
Duration of ECC (hr) 1.21 ± 0.62 1.59 ± 0.79 <0.001
Use of intra-aortic balloon pump (%) 6 14 0.03
Postoperative cardiovascular SOFA
score 0 or 1, 2, 3 or 4 (%)
51, 0, 49 27, 2, 71 <0.001
Any perioperative transfusions (%)
Red blood cells 50 79 <0.001
Fresh frozen plasma 20 35 0.005
Platelets 19 37 <0.001
Any pentastarch 10% receivedb (%) 43 56 0.06
Any albumin received (%) 14 38 <0.001
aResults are expressed as mean ± standard deviation, median (interquartile
range) or percent, as appropriate. bThe dose of pentastarch was associated
with acute kidney injury (AKI) (see Figure 3). Sex, age, ethnicity, smoking
status, prior history, initial estimated glomerular filtration rate, other
medication, urgent surgery, need for reintervention and amount of crystalloids
and hydroxyethyl starch 6% were not statistically associated with AKI. ECC,
extracorporeal circulation; LVEF, left ventricular ejection fraction; SOFA,
Sequential Organ Failure Assessment score.use of HES 6%. There was a dose-dependent risk for AKI
with the use of albumin and pentastarch 10% (Figure 3).
This association was not seen with HES 6% or crystalloids.
Sex, age, ethnicity, smoking status, prior history, initial
GFR, other medications, urgent surgery and need for
reintervention were not statistically associated with AKI.
Using the AKIN stage 1 definition of AKI, we identified
the same predictors we did with the RIFLE risk. In addition,
older age, lower initial GFR, history of diabetes, history of
hypertension and preoperative renin angiotensin blockade
were associated with AKIN stage 1 (data not shown).
Risk of acute kidney injury with albumin administration in
propensity-matched patients
The adjustment for selection bias was further addressed
using a propensity score. Because albumin administration
was identified as a novel risk factor of AKI following cardiac
surgery, we further studied this finding by pairing those
who received albumin with similar individuals who did not.
Albumin administration was associated with multiple
clinical variables, including age, LVEF, heart valve surgery,
GFR, cardiovascular SOFA score, fluids (crystalloids, HES
6% and pentastarch 10%), transfusions (RBCs, FFP and
platelets), preoperative hemoglobin, duration of ECC and
use of diuretics. We derived the probability of receiving
albumin (propensity score) with logistic regression
using variables associated with its use, and then we
matched individuals with a similar risk profile (propensity
score ±0.05) who either received albumin or did not. Our
ratio of variable/event was 8.3. Using a caliper size of 0.2
times, the standard deviation of the propensity score
would have been similar at 0.042. Within the group of 153
individuals given albumin, we could match 141 of them to
141 similar controls. Risk factors for AKI between these
groups were balanced, including the amount of fluid
administered (82 ± 35 ml/kg without albumin compared
to 78 ± 30 ml/kg with albumin, P = 0.28). The only
exception was the volume of pentastarch 10%, which was
lower in the albumin group (Table 3). Despite this, the risk
for AKI associated with the use of albumin remained
statistically higher (RIFLE risk: 12% versus 5%, P = 0.03;
AKIN stage 1: 28% versus 13%, P = 0.002).
With regard to the timing of AKI, both groups
satisfied the creatinine criteria at the same time. In
the propensity-matched group that received albumin,
20 stage 1 AKI events occurred before 36 hours, 15
occurred between 36 and 48 hours and 5 occurred
after 48 hours. The group that did not receive albumin
had 10 events before 36 hours, 9 between 36 and 48 hours
and none thereafter. The proportions were similar in both
groups. Had AKI diagnosed prior to 36 hours influenced
the prescription of albumin, we would have expected
a trend toward an earlier diagnosis of AKI in the albumin
group.
Figure 3 Univariate dose–response risk for acute kidney injury using colloids. The number of patients per category is shown in parentheses.
Spearman’s correlation was used to test the association between tertiles of colloids and acute kidney injury (AKI). HES, Hydroxyethyl starch.
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propensity-matched patients with a perioperative
cardiovascular SOFA score of zero
We also addressed the subgroup of individuals without
hemodynamic instability as defined by a perioperative
cardiovascular SOFA score of zero (n = 490). Within this
subgroup, we derived a new propensity score predictive
of the use of albumin with the same defining variablesTable 3 Risk of acute kidney injury with albumin administrati
Age (yr)
GFR (ml/min/1.73 m2)
LVEF ≤35%, 36% to 49%, ≥50% (%)
Preoperative hemoglobin (g/L)
Diuretics (%)
Heart valve surgery (%)
Duration of ECC (hr)
Cardiovascular SOFA score (immediately postoperatively) ≤2, >2 (%)
Crystalloids perioperatively until 36 hr postoperativelyb (ml/kg)
Any HES 6% perioperatively until 36 hr postoperatively (%)
Dose of HES 6% receivedb (ml/kg)
Any pentastarch 10% perioperatively until 36 hr after surgery (%)
Dose of pentastarch 10% receivedb (ml/kg)
Red blood cell transfusions, 0, 1, 2, 3+ U (%)
Fresh frozen plasma transfusions, 0, ≤5, >5 U (%)
Platelet transfusions, 0, ≤10, >10 U (%)
AKI
AKIN stage 1 (%)
RIFLE risk (%)
RIFLE injury (%)
aAKI, Acute kidney injury; AKIN, Acute Kidney Injury Network; ECC, Extracorporeal ci
ventricular ejection fraction; RIFLE, Risk, injury, failure, loss and end-stage kidney dis
range (IQR)) value given applies to the subgroup that received the colloid.that we used for the entire cohort. We were able to
match 50 cases to 50 controls with a similar risk profile,
all of whom had a perioperative cardiovascular SOFA
score of zero (Table 4). There was a 57% patient overlap
with the group described above. The risk factors for AKI
also balanced out between the two groups, except for a
lower dose of pentastarch and a higher rate of RBC
transfusions in the albumin group. Even in this differenton in propensity-matched patientsa
No albumin (n = 141) Any albumin (n = 141) P-value
70 ± 9 69 ± 9 0.81
62 ± 18 62 ± 20 0.78
14, 11, 75 13, 19, 68 0.13
127 ± 18 127 ± 19 0.99
50 50 1.00
35 31 0.45
1.5 ± 0.7 1.6 ± 0.8 0.94
34, 66 38, 62 0.52
82 ± 35 78 ± 30 0.28
85 91 0.10
16 (9 to 23) 14 (8 to 20) 0.30
38 36 0.71
13 (8 to 18) 8 (5 to 16) 0.03
30, 9, 15, 45 19, 16, 20, 45 0.07
67, 28, 5 67, 23, 10 0.70




rculation; GFR, Glomerular filtration rate; HES, Hydroxyethyl starch; LVEF, Left
ease; SOFA, Sequential Organ Failure Assessment. bThe median (interquartile
Table 4 Risk of acute kidney injury with albumin administration in propensity-matched patients with a perioperative
cardiovascular Sequential Organ Failure Assessment score of zeroa
No albumin (n = 50) Any albumin (n = 50) P-value
Age (yr) 70 ± 9 69 ± 9 0.81
GFR (ml/min/1.73 m2) 62 ± 19 63 ± 17 0.99
LVEF ≤35%, 36% to 49%, ≥50% (%) 10, 12, 78 5, 16, 79 0.78
Preoperative hemoglobin (g/L) 130 ± 16 127 ± 19 0.26
Diuretics (%) 46 46 1.00
Heart valve surgery (%) 24 18 0.47
Duration of ECC (hr) 1.2 ± 0.5 1.2 ± 0.5 0.63
Crystalloids perioperatively until 36 hr postoperativelyb (ml/kg) 76 ± 31 75 ± 26 0.89
Any HES 6% received perioperatively until 36 hr postoperatively (%) 84 90 0.38
Dose of HES 6% receivedb (ml/kg) 16 (11 to 22) 12 (7 to 18) 0.10
Any pentastarch 10% perioperatively until 36 hr postoperatively (%) 50 48 0.84
Dose of pentastarch 10% receivedb (ml/kg) 14 (9 to 20) 6 (4 to 15) 0.02
Red blood cell transfusions, 0, 1, 2, ≥3 U (%) 36, 14, 14, 35 11, 11, 37, 42 0.05
Fresh frozen plasma transfusions, 0, ≤5, >5 U (%) 69, 25, 6 58, 42, 0 0.21
Platelet transfusions, 0, ≤10, >10 U (%) 78, 20, 2 68, 32, 0 0.44
AKI
AKIN stage 1 (%) 8 30 0.005
RIFLE risk (%) 4 12 0.14
RIFLE injury (%) 4.0 4.0 1.00
aAKIN, Acute Kidney Injury Network; AKI, Acute kidney injury; ECC, Extracorporeal circulation; GFR, Glomerular filtration rate; HES, Hydroxyethyl starch; LVEF, Left
ventricular ejection fraction; RIFLE, Risk, injury, failure, loss and end-stage kidney disease; SOFA, sequential organ failure assessment score. bThe median (IQR) given
applies to the subgroup that received the colloid.
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stage 1 AKI (30% versus 8%, P = 0.005).
Discussion
In our present study, we found that albumin administration
was associated with a dose-dependent increased risk of AKI
in patients undergoing cardiac surgery. To further assess
the risk associated with albumin and adjust for potential
indication biases, we paired individuals who received
albumin to controls who received no albumin. On the
basis of this propensity score, albumin administration
was still associated with a twofold increased risk for AKI.
We repeated this methodology in individuals without
significant postoperative hemodynamic instability and
found similar results.
To our knowledge, this is the first study to show a
dose–response relationship between albumin adminis-
tration and increased risk for AKI. Our study offers new
insights into the association between albumin administra-
tion and kidney function. Current evidence regarding the
beneficial or deleterious effect of albumin in this context is
inconclusive, especially in surgical patients and those
without hypoalbuminemia [4,8-10,12,21-23]. In recent
international consensus statements and guidelines on AKI
and fluid administration [7,11], experts have recommendedthe use of crystalloids ahead of albumin in patients at
risk for or with AKI and advised against the use of
hyperoncotic albumin solutions for fluid resuscitation.
Most of the evidence in support of these recommendations
originates from the CRYCO Study Group [10]. In their
observational study of 1,013 patients with shock, hyperon-
cotic albumin was associated with a fivefold increased risk
of renal event, defined as a twofold increase in creatinine
or need for dialysis [10]. The authors did not report any
dose–response relationship between albumin administra-
tion and risk for AKI. Of note, patients with cirrhosis, the
group from which most of the evidence regarding the
beneficial effect of albumin on kidney function derives,
were excluded from the study [8,22,23]. The results of
other small studies have suggested a deleterious effect of
albumin on kidney function, but they had limited statistical
power [21,24-26] or involved very large doses of albumin
(more than 1,100 g per patient) [24].
In contrast to these findings, other studies have shown a
protective or neutral effect on kidney function due to albu-
min administration [4,9,12,27]. In a recent meta-analysis,
the protective effect of albumin on kidney function seemed
to be present in patients with cirrhosis [9]. In the largest
RCTconducted to date on albumin administration in critic-
ally ill patients (the Saline versus Albumin Fluid Evaluation
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of mortality and severe AKI compared to crystalloids [4].
Severe AKI was defined as a creatinine level >300 μmol/L
and/or need for dialysis. However, the safety profile of
albumin was not consistent between subgroups, with
patients with traumatic brain injury having increased
mortality [28] and patients with sepsis having decreased
mortality [29]. There were no reports on kidney function
in the traumatic brain injury post hoc study [28] and no
increased rate of severe AKI associated with albumin in
the septic subgroup [29]. In comparison, the ALBIOS
study investigators looked at the effect of hyperoncotic
albumin in patients with severe sepsis and septic shock
and did not find any difference in either mortality as the
primary outcome or in severe AKI, defined as a creatinine
level >300 μmol/L [12]. The authors also looked at
the incidence of AKI based on RIFLE criteria in a
post hoc analysis and did not find a difference between
the two groups [12]. The timing of AKI and albumin
administration were not defined in the study. Importantly,
the ALBIOS study differed from the other studies, as
albumin 20% was administered on a daily basis if the
patient’s albumin level was below 30 g/L and not according
to the clinical context [12]. In addition, the cumulative fluid
balance was lower in the albumin group, which could have
reduced mortality and morbidity in that group [30-32]. In
our present study, we included in our propensity
score analysis the amount of fluid received by 36 hours
after surgery to address this bias.
As highlighted in previous studies, the effect of albumin
administration seems to differ between subgroups [27-29].
In our present study, we included patients undergoing
cardiac surgery, a population with very limited data and a
different pathophysiological model of AKI than patients
with severe sepsis [21,33,34]. In a recent systematic
review, authors highlighted the need for additional studies
on albumin administration in surgical patients [35]. In
cardiac surgery, a small study suggested that albumin may
have a deleterious effect on kidney function [21], whereas
another found no difference [34]. In the most recent study
on this subject, researchers compared pentastarch, 25%
albumin (75 g) and Ringer’s lactate solution and did not
find any differences in creatinine levels between the
three groups [33]. Of note, cardiac surgery patients
were excluded from the SAFE trial [4], and only 6%
to 7% of patients in the ALBIOS study had elective
surgery [12]. The type of surgery was not mentioned
in the ALBIOS study.
Our study was not designed to investigate underlying
biological mechanisms to explain the effect of albumin
on kidney function. Postmortem examinations of a limited
number of patients who received large doses of 25% albu-
min showed no evidence of abnormal albumin storage [36].
The results of basic science studies on the renal impact ofalbumin administration have been contradictory [37].
Albumin may have anti-inflammatory and antioxidant
properties to protect against organ damage [35,38,39].
However, although there are a number of mechanisms
by which albumin might exert a beneficial effect, they
are as yet unproven. In opposition to popular belief,
according to the Starling equation, glomerular filtration
pressure decreases as intracapillary oncotic pressure
increases more than hydrostatic pressure, a situation
favored by the use of hyperoncotic colloids [37]. This
principle may partly explain our findings regarding the
dose-relationship effect between the risk of AKI and the
amount of albumin administered. In light of recent
findings supporting the beneficial effect of chloride-
restrictive fluid administration on kidney function
[40], we ensured that albumin solutions had similar or
lower chloride concentrations compared to normal saline,
and we confirm that the use of crystalloids with lower
chloride content was minimal at our institution when the
study was conducted.
Although our present study was focused on kidney
function as a primary endpoint, perioperative kidney
function is a very relevant parameter in predicting long-
term outcomes [41-43]. AKI is an important independent
predictor of postdischarge mortality in patients undergoing
cardiac surgery [41-43]. Other large studies have confirmed
these findings in a broader population [44,45] as well as the
deleterious influence of AKI on the development of chronic
kidney disease (CKD) and ESRD [45,46]. Even mild AKI,
defined as an increase in serum creatinine by 27 μmol/L
(0.3 mg/dl), is associated with an increase in mortality
[42,44,47,48], development of CKD [49], increased length of
stay [48] and costs [47]. Importantly, some of these studies
were conducted in patients undergoing cardiothoracic
surgery, as in our study population [42,48].
Our study has several strengths. It is the largest study to
date on the effect of albumin administration on kidney
function in patients undergoing cardiac surgery, a
clinical setting with very limited data and a different
pathophysiological model of AKI than severe sepsis or
shock. We were able to demonstrate a twofold increase
risk in AKI after adjustment with a propensity score that
included baseline characteristics, surgical aspects, severity
of illness scores and amounts of blood products, colloids
and crystalloids administered. As recently shown, propen-
sity scores may underestimate the true effect size com-
pared to RCTs in critically ill patients [20]. The use of a
propensity score in our study could therefore underesti-
mate the effect of albumin on the risk of developing
AKI. Importantly, we have shown, for the first time to our
knowledge, a dose–response relationship between albumin
administration and risk for AKI in this population.
Our study also has limitations inherent to its retrospective
and single-center design. First, there is a concern regarding
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optimize left ventricular end-diastolic filling pressure using
colloids. However, 86% of surgeries were elective, and any
unstable condition was likely to surface after ECC at the
end of the surgery. Our propensity score included the
postoperative cardiovascular SOFA score. In addition, we
obtained similar results in patients who had cardiovascular
SOFA scores of zero. Second, we assessed whether the use
of albumin by clinicians wishing to avoid giving patients
synthetic colloids in the setting of impending AKI could
have been a consequence of early AKI rather than its cause.
However, the timing of AKI was similar in both groups.
Third, it is possible that the period between the onset of
oliguria and the rise of creatinine was a window within
which albumin may have been preferred over synthetic
colloids, again in the setting of impending AKI. However,
we would have expected at least a trend toward greater
use of crystalloids in the albumin group; however, the
doses of crystalloids were not statistically different
between groups (and lower in absolute numbers in the
albumin group), even when addressing diagnosis of
AKI <36 hours, 36 to 48 hours and >48 hours after
surgery separately. We also had limited data on albumin
levels. Recent studies have suggested a relationship
between hypoalbuminemia and risk for AKI [50,51]. In
our center, the postoperative prescription of albumin does
not rely on a preoperative serum albumin value, as
albumin is not often measured. Whether this could still be
a confounder remains unknown. Some authors have
suggested that albumin administration may improve
morbidity once the albumin levels are increased up to
30 g/L [39,52], whereas others did not report such results
[12]. As the majority of our patients had nonurgent
surgeries, it is unlikely that their baseline albumin levels
would have been <30 g/L. We did not have data on
emerging biomarkers for AKI. Current observational
studies still rely on serum creatinine for making an AKI
diagnosis, as these emerging biomarkers are not largely
available even today. Furthermore, as mentioned, AKI, as
defined by serum creatinine changes, is a relevant end-
point because it is strongly associated with increased mor-
tality and morbidity. Finally, we cannot rule out that
the association between albumin administration and
AKI may have resulted from a selection bias. There
also might be unknown confounding factors for which
we were unable to adjust.
Conclusions
We found that albumin administration was associated
with a twofold increased risk for AKI after adjustment
with a propensity score in cardiac surgery patients, a
population with a different pathophysiological model of
AKI than severe sepsis or shock and with limited data
on the effect of albumin administration. The detrimentaleffect was proportional to the dose administered. The
results of this study are in accordance with recent guide-
lines suggesting the use of crystalloid solutions for most
patients with or at risk for AKI [7,11]. Future RCTs
should address the safety of albumin in terms of dose
and concentration compared to crystalloids in cardiac sur-
gery patients.
Key messages
 In a retrospective cohort study including 984
patients undergoing cardiac surgery, we found
that albumin administration was a risk factor
for AKI.
 This finding remained significant when we used a
propensity score methodology, even in patients
without postoperative hemodynamic instability.
 We also identified a dose–response relationship
between albumin administration and the risk
for AKI.
 Future RCTs should address the safety of albumin in
terms of dose and concentration compared to
crystalloids in cardiac surgery.
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